## Anti-CD49d Antibody Treatment Improves Survival and Attenuates Neurocognitive Deficits after Traumatic Brain Injury in Aged Mice

## **M Northwestern** Medicine<sup>®</sup> Feinberg School of Medicine

Zhangying Jennie Chen<sup>1,2</sup>, Kacie P Ford<sup>2</sup>, Mecca BAR Islam<sup>2</sup>, Booker T Davis IV<sup>2</sup>, and Steven J Schwulst<sup>2</sup> <sup>1</sup>Driskill Graduate Program in Life Sciences, <sup>2</sup>Department of Surgery, Division of Trauma and Critical Care

Traumatic brain injury (TBI) afflicts approximately seventy million people worldwide yearly <sup>1</sup>. While TBI affects individuals of all ages, the elderly (aged 65 years and older) experience higher mortality and more severe consequences than younger individuals. Recently, studies have found that age introduces T cells into the brain, likely due to the structural and functional alterations of the blood brain barrier (BBB)<sup>2</sup>. Previously, we have observed that aged mouse brains showed significant CD8<sup>+</sup> T cells two months post-TBI. These T cells were largely effector memory (EM) cells. They were more activated and pro-inflammatory<sup>3</sup>. Herein, utilizing anti-CD49d antibody (aCD49d Ab) to reduce the invasion of circulating lymphocytes, we are interested in gaining more insight on the presence and function of these T-cells. We hypothesize that blocking infiltration of peripheral T-cells into the injured brain would improve neurocognitive outcomes in aged mice after TBI.



## Introduction & Hypothesis

<sup>1</sup>Maiden et al., Am J Respir Crit Care Med. 2020 <sup>2</sup>Schetters et al., Front. Immunol. 2018 <sup>3</sup>Chen et al., Shock 2023